Results 1 to 10 of about 125,924 (124)

Triple-Negative Breast Cancer

International Journal of Breast Cancer, 2012
Ever since the seminal work that was published by Perou et al., triple-negative breast cancer (TNBC) has become a common lexicon among clinicians who care for patients with breast cancer. Beside portending a poor outcome, TNBC is unique in that, unlike the hormone-positive and Her-2-positive cancer cells, it lacks target specific therapy.
Quyen D. Chu, Tari King, Thelma Hurd
doaj   +8 more sources

Triple-negative breast cancer [PDF]

Wiener Medizinische Wochenschrift, 2010
Recent advances in biological characterization of breast cancer have eventually increased our understanding of underlying tumour biology. While for endocrine responsive and Her2-positive disease different molecular targeted therapies are available, up to now no specific targeted approach for triple-negative breast cancer has been developed.
Rupert, Bartsch, Reinhard, Ziebermayr, Christoph C, Zielinski, Guenther G, Steger   +3 more
  +13 more sources

Triple Negative Breast Cancer

Asian Pacific Journal of Cancer Prevention, 2014
Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2), have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed.
Idil, Cetin, Mehmet, Topcul
  +9 more sources

Male Triple-Negative Breast Cancer [PDF]

Cureus, 2021
Male breast cancer is a rarely encountered disease, when compared with female breast cancer, often detected in more advanced stage at the time of diagnosis, and associated with more lymph node metastasis rates, more estrogen receptors positivity, and less human epidermal growth factor receptor-2 expression (HER-2) rates.
Qavi, Qasif, Alkistawi, Firas, Kumar, Shashi, Ahmed, Rizwan, Saad Abdalla Al-Zawi, Abdalla   +4 more
openaire   +2 more sources

Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer

Journal for ImmunoTherapy of Cancer, 2022
Background Triple-negative breast cancer is characterized by a poor prognosis and lack of targeted treatments, and thus, new targeting markers and therapeutic strategies are urgently needed.
Cong Chen, Linbo Wang, Xun Zhang, Ling Xu, Misha Mao, Yongxia Chen, Jingjing Yang, Yifan Cheng, Feiyang Ji, Jichun Zhou, Zhaoqing Li, Siwei Ju, Jiahang Zhang   +12 more
doaj   +1 more source

Triple Negative Breast Cancer [PDF]

Klinicka onkologie, 2015
In the Czech Republic, around 6,500 women get breast cancer each year; out of this number, nearly 1,000 women are triple negative subtype. Triple negative breast cancer is characterized by lack of expression of α-estrogen, progesterone, and HER2 receptors.
J, Navrátil, P, Fabian, M, Palácová, K, Petráková, R, Vyzula, M, Svoboda   +5 more
openaire   +2 more sources

Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy. [PDF]

PLoS ONE, 2015
Triple-negative breast cancer is a high-risk breast cancer with poor survival rate. To date, there is a lack of targeted therapy for this type of cancer. One unique phenomenon is that inflammatory breast cancer is frequently triple negative.
Zining Jin, Wenqian Wang, Nan Jiang, Lei Zhang, Yiming Li, Xiaoyin Xu, Shouliang Cai, Liang Wei, Xuhong Liu, Guanglei Chen, Yizhen Zhou, Cheng Liu, Zhan Li, Feng Jin, Bo Chen   +14 more
doaj   +1 more source

Metabolic Reprogramming in Triple-Negative Breast Cancer

Frontiers in Oncology, 2020
Metabolic reprogramming is an emerging hallmark of cancer cells, in which cancer cells exhibit distinct metabolic phenotypes to fuel their proliferation and progression.
Xiangyu Sun, Mozhi Wang, Mengshen Wang, Xueting Yu, Jingyi Guo, Tie Sun, Xinyan Li, Litong Yao, Haoran Dong, Yingying Xu   +9 more
doaj   +1 more source

HJURP regulates cell proliferation and chemo-resistance via YAP1/NDRG1 transcriptional axis in triple-negative breast cancer

Cell Death and Disease, 2022
Triple-negative breast cancer is still a difficult point in clinical treatment at present, and a deep study of its pathogenesis has great clinical value. Therefore, our research mainly focuses on exploring the progression of triple-negative breast cancer
Misha Mao, Yunlu Jia, Yongxia Chen, Jingjing Yang, Ling Xu, Xun Zhang, Jichun Zhou, Zhaoqing Li, Cong Chen, Siwei Ju, Linbo Wang   +10 more
doaj   +1 more source

MiR-133 Targets YES1 and Inhibits the Growth of Triple-Negative Breast Cancer Cells

Technology in Cancer Research & Treatment, 2020
Triple-negative breast cancer shows worse outcome compared with other subtypes of breast cancer. The discovery of dysregulated microRNAs and their roles in the progression of triple-negative breast cancer provide novel strategies for the treatment of ...
Guochen Zhang MD, Junlan Wang BS, Ruilin Zheng MD, Beibei Song BS, Li Huang PhD, Yujiang Liu MD, Yating Hao MD, Xiangdong Bai PhD   +7 more
doaj   +1 more source